Cyclosporin CCAS# 59787-61-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 59787-61-0 | SDF | Download SDF |
| PubChem ID | 5287817 | Appearance | Powder |
| Formula | C62H111N11O13 | M.Wt | 1218.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-[(1R)-1-hydroxyethyl]-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone | ||
| SMILES | CC=CCC(C)C(C1C(=O)NC(C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)O)O | ||
| Standard InChIKey | JTOKYIBTLUQVQV-QRVTZXGZSA-N | ||
| Standard InChI | InChI=1S/C62H111N11O13/c1-25-26-27-39(14)52(76)51-56(80)66-49(42(17)74)60(84)67(18)32-47(75)68(19)43(28-33(2)3)55(79)65-48(37(10)11)61(85)69(20)44(29-34(4)5)54(78)63-40(15)53(77)64-41(16)57(81)70(21)45(30-35(6)7)58(82)71(22)46(31-36(8)9)59(83)72(23)50(38(12)13)62(86)73(51)24/h25-26,33-46,48-52,74,76H,27-32H2,1-24H3,(H,63,78)(H,64,77)(H,65,79)(H,66,80)/b26-25+/t39-,40+,41-,42-,43+,44+,45+,46+,48+,49+,50+,51+,52-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Cyclosporin C Dilution Calculator
Cyclosporin C Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.8206 mL | 4.1031 mL | 8.2061 mL | 16.4123 mL | 20.5153 mL |
| 5 mM | 0.1641 mL | 0.8206 mL | 1.6412 mL | 3.2825 mL | 4.1031 mL |
| 10 mM | 0.0821 mL | 0.4103 mL | 0.8206 mL | 1.6412 mL | 2.0515 mL |
| 50 mM | 0.0164 mL | 0.0821 mL | 0.1641 mL | 0.3282 mL | 0.4103 mL |
| 100 mM | 0.0082 mL | 0.041 mL | 0.0821 mL | 0.1641 mL | 0.2052 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 6beta-Angeloyloxy-1beta,10beta-epoxy-9-oxofuranoeremophilane
Catalog No.:BCN7600
CAS No.:59780-08-4
- Boc-Asp(OMe)-OH.DCHA
Catalog No.:BCC3367
CAS No.:59768-74-0
- Cudraflavanone B
Catalog No.:BCN3446
CAS No.:597542-74-0
- 1beta,10beta-Epoxy-6beta-isobutyryloxy-9-oxofuranoeremophilane
Catalog No.:BCN7601
CAS No.:59742-11-9
- beta-Amyrin palmitate
Catalog No.:BCN4099
CAS No.:5973-06-8
- Citalopram hydrobromide
Catalog No.:BCC7063
CAS No.:59729-32-7
- Camostat Mesilate
Catalog No.:BCC4894
CAS No.:59721-29-8
- Piperacillin Sodium
Catalog No.:BCC4704
CAS No.:59703-84-3
- Cephalexin hydrochloride
Catalog No.:BCC4095
CAS No.:59695-59-9
- 6alpha-Hydroxyhispanone
Catalog No.:BCN7416
CAS No.:596814-48-1
- 3-O-Acetyl-beta-boswellic acid
Catalog No.:BCN2672
CAS No.:5968-70-7
- Calyciphylline A
Catalog No.:BCN4098
CAS No.:596799-30-3
- Vindolinine
Catalog No.:BCN7822
CAS No.:5980-02-9
- UK 14,304
Catalog No.:BCC5226
CAS No.:59803-98-4
- Tenoxicam
Catalog No.:BCC4733
CAS No.:59804-37-4
- Ajmalimine
Catalog No.:BCN3420
CAS No.:59846-31-0
- Synephrine HCl
Catalog No.:BCC4359
CAS No.:5985-28-4
- Palustrol
Catalog No.:BCN4100
CAS No.:5986-49-2
- Patchouli alcohol
Catalog No.:BCN4966
CAS No.:5986-55-0
- Cyclosporin A
Catalog No.:BCC4773
CAS No.:59865-13-3
- Oxybuprocaine HCl
Catalog No.:BCC4691
CAS No.:5987-82-6
- Glabridin
Catalog No.:BCN1221
CAS No.:59870-68-7
- L-Dihydroorotic acid
Catalog No.:BCC9007
CAS No.:5988-19-2
- N-Formyl-Met-Leu-Phe
Catalog No.:BCC7205
CAS No.:59880-97-6
Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors.[Pubmed:12873538]
J Heart Lung Transplant. 2003 Jul;22(7):715-22.
BACKGROUND: Cyclosporin (CsA) dose selection is complicated by significant pharmacokinetic variability between patients. Although therapeutic drug monitoring (TDM) has proven to be a useful tool for dose individualization, the search for an effective and practical measure of clinical effect has uncovered a number of options. Monitoring the CsA concentration in a blood sample taken 2 hours after the dose (C(2)) has been utilized but has not been rigorously evaluated in all clinical situations. The aim of this study was to evaluate C(2) and trough (C(0)) CsA concentrations as surrogate markers of area under the concentration-time curve (AUC) in stable, long-term heart transplant recipients receiving CsA alone or with diltiazem and/or ketoconazole. METHODS: CsA blood concentration-time data were collected at steady state for 47 stable heart transplant recipients after the morning dose of Neoral. CsA concentration in whole blood was quantitated using the EMIT immunoassay. Patients were stratified into 4 groups, depending on the long-term concomitant administration of drugs known to inhibit CsA metabolism, as part of their routine therapy: Group A (n = 11), CsA alone; Group B (n = 10), CsA with slow-release diltiazem; Group C (n = 13), CsA with ketoconazole; and Group D (n = 12), CsA with a combination of diltiazem and ketoconazole. RESULTS: In Group A, C(2) correlated poorly with AUC(0-5) (r(2) = 0.197; p = 0.17), whereas C(0) (trough blood sample) showed a stronger correlation (r(2) = 0.710; p = 0.001). Correlations of C(0) and C(2) with AUC(0-5) were the same, but weaker in patients receiving CsA and diltiazem (r(2) = 0.650; p = 0.005); however, C(2) correlated strongly with AUC(0-5) in patients receiving ketoconazole (r(2) = 0.870; p < 0.0001) or ketoconazole with diltiazem (r(2) = 0.898; p < 0.0001). C(0) was a poor predictor of AUC(0-5) in the latter 2 groups. CONCLUSIONS: C(2) showed a strong correlation with AUC(0-5) in cardiothoracic transplant recipients receiving CsA with ketoconazole, but not with CsA alone or diltiazem. TDM using C(2) as an estimate of AUC requires further evaluation before being applied in long-term, stable cardiac transplant patients, as it may lead to inappropriate dose adjustment of CsA in patients receiving concomitant metabolic inhibitors.
